KBC Securities - MDXHEALTH (MDXH) mdxhealth Strong preliminary Q2 results trigger guidance upgrade

Report

KBC Securities

Thomas Vranken

mdxhealth Strong preliminary Q2 results trigger guidance upgrade

mdxhealth's preliminary 2Q24 results feature a continued strong uptake in revenues to $ 22.2m (+32% y/y). We presume the new germline test has started contributing revenue as of Q2 as planned, and on the back of strong growth prospects management again raised its FY24 revenue guidance to $ 85-87m i.e., 23% growth y/y. The company expresses confidence in reaching adjusted EBITDA profitability in 1H25. We maintain our $ 6 TP and re-iterate our Buy rating.

08/07/2024 1 EN

Underlying

MDXHEALTH

See profile

BE0974461940 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : AGFB BB, DSFIR NA, IVA FP, MDXH BB

: AGFB BB, DSFIR NA, IVA FP, MDXH BB

February 17, 2026 February 17, 2026 1 EN

KBC Securities

mdxhealth ExoDx boosts 2026 growth expectations

Following mdxhealth preliminary 2025 full-year sales and 2026 sales guidance in the $ 137-140m range, we update our model and raise 2026 revenue estimates to $ 139.9m, driven by ExoDx and synergy potential with the GPS test. The ExoDx acquisition should ensure the company's high growth profile, and the increased scale should allow for further operational leverage. That said, we note that the company will likely require additional funding to cover cash outflow obligations. Given the high growth outlook and operational leverage potential, we reiterate our BUY and raise our TP to $ 6 from $ 4.2.

February 17, 2026 February 17, 2026 1 EN

GlobeNewsWire

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title...

February 12, 2026 February 12, 2026 1 EN

Umicore Feedback FY25 results conference call

Below are the highlights from the conference call. We remind that FY25 adjusted EBITDA increased by 11% to 847m, slightly above the high end of the 790-840m guidance range (in line with KBCS estimate, 1% above consensus). The company did not give a precise guidance on FY26 although sounded cautious on developments in the EV industry. The strong metal price environment will partly be offset by lower hedging levels for 2026 and maintenance, while new longer term hedges generate additional earnings visibility at very attractive levels for a longer period of time. We maintain our Accumulate rating...

February 20, 2026 February 20, 2026 1 EN

Hilde Van Boxstael ... (+5)

Hilde Van Boxstael
Lynn Hautekeete
Mathijs Geerts Danau
Wim Hoste
Wim Lewi

Morning Notes : COFB BB, GLPG NA, UMI BB

: COFB BB, GLPG NA, UMI BB

February 20, 2026 February 20, 2026 1 EN

Lynn Hautekeete

Lynn Hautekeete

Cofinimmo FY25 results above expectations, guidance below

Cofinimmo reports recurring EPRA EPS +1,1% above our estimates and 4,0% above its guidance. The earnings beat is driven by higher like-for-like rental income at +2,9%. The EPRA EPS outlook of FY26 is below our estimates at € 6,35 vs € 6,39 KBCSe. The guided debt ratio at YE26 is 340 bps higher than our expectations at 44,0% due to only € 110,0m guided asset disposals and higher than expected investments at € 310,0m which will mainly impact FY27/28 rental income. In the medium term, the focus should be on refinancings. The average debt maturity is low at 3x which is related to the ongoing excha...

February 20, 2026 February 20, 2026 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

mdxhealth Strong preliminary Q2 results trigger guidance upgrade

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : AGFB BB, DSFIR NA, IVA FP, MDXH BB

mdxhealth ExoDx boosts 2026 growth expectations

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Umicore Feedback FY25 results conference call

Morning Notes : COFB BB, GLPG NA, UMI BB

Cofinimmo FY25 results above expectations, guidance below

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe